ANTIFUNGAL PA SUMMARY

PREFERRED	ciclopirox nail lacquer, fluconazole tablets/oral
	suspension/injection, itraconazole capsules,
	terbinafine tablets
NON-PREFERRED	CNL8 Nail Kit, Lamisil tablets, Lamisil oral
	granules, Noxafil, Penlac nail lacquer,
	Sporanox capsules and pulsepak, Sporanox
	oral solution, Terbinex kit, Vfend

LENGTH OF AUTHORIZATION: Varies based on drug and diagnosis

PA CRITERIA:

For fluconazole injection

Medication must be administered in member's home by home health or in a long-term care facility.

For terbinafine (Lamisil) tablets

❖ Approvable for the treatment of onychomycosis. Submit documentation of positive KOH preparation, fungal culture, or nail biopsy.

For Lamisil oral granules

❖ Approvable for the treatment of tinea capitis in members 4-12 years of age. Submit documentation of allergies, drug-drug interactions, contraindications, or a history of intolerable side effects to griseofulvin.

For ciclopirox (Penlac) or CNL8

- ❖ Approvable for the treatment of mild to moderate onychomycosis or white superficial onychomycosis in members with diabetes mellitus or peripheral vascular disease. Submit documentation of positive fungal culture result.
- ❖ Approvable for the treatment of moderate to severe onychomycosis in members with diabetes mellitus, peripheral vascular disease, or immunocompromised status. Submit documentation of positive fungal culture result AND allergies, drug-drug interactions, contraindications, or a history of intolerable side effects to terbinafine (Lamisil).

For itraconazole (Sporanox capsules or pulsepak)

- ❖ Approvable for the treatment of onychomycosis. Submit documentation of allergies, drug-drug interactions, contraindications, or a history of intolerable side effects to terbinafine (Lamisil) AND positive KOH preparation, fungal culture, or nail biopsy.
- ❖ Approvable for the diagnosis of aspergillus, blastomycosis, or histoplasmosis.
- ❖ Approvable for the diagnosis of tinea versicolor, tinea cruris, tinea corporis, or tinea pedis when infections involve a large area of the body or the member is immunocompromised.

For Noxafil

Noxafil is approvable for the following diagnoses:

- Preventative therapy for invasive aspergillus and/or candida in immunocompromised members
- o Invasive aspergillosis, zygomycosis, fusariosis, or other moulds that are resistant to previous systemic antifungal therapy
- Noxafil is also approvable for oropharyngeal candidiasis refractory to itraconazole or fluconazole *OR* submit documentation of allergies, contraindications, drug-drug interactions, or a history of intolerable side effects to itraconazole or fluconazole.
- Noxafil is also approvable for continuation of therapy following discharge from a hospital for certain diagnoses.

For Sporanox oral solution

- ❖ Approvable for the diagnosis of oropharyngeal candidiasis (thrush), esophageal candidiasis, or empiric febrile neutropenia.
- ❖ Approvable in patients meeting Sporanox capsules or pulsepak criteria who are unable to swallow capsules.

For Terbinex Kit

❖ Terbinafine tablets are preferred and also require PA. If terbinafine tablets cannot be used, submit a written letter of medical necessity detailing reason(s).

For Vfend

- ❖ Approvable for members using oral Vfend for continuation of therapy after being started on IV Vfend therapy
- ❖ Approvable for members who have tried one other systemic antifungal agent and who have one of the following diagnoses:
 - o Esophageal candidiasis
 - o Invasive aspergillus
 - o Fungal infection caused by Scedosporium apiospermum
 - o Fungal infection caused by Fusarium species
 - o Candidemia in nonneutropenic patient
 - o Disseminated Candida skin infection
 - o Candida infection in abdomen, kidney, bladder wall, or wound

EXCEPTIONS:

- ❖ Exceptions to these conditions of coverage are considered through the prior authorization process.
- ❖ The Prior Authorization process may be initiated by calling SXC Health Solutions at 1-866-525-5827.

PA and APPEAL PROCESS:

❖ For online access to the PA process please go to www.ghp.georgia.gov, select the Provider Information tab, click on "view full text" in the Pharmacy Services box, click on "Prior Approval Process" in the list on the left.

QUANTITY LEVEL LIMITATIONS:

❖ For online access to the current Quantity Level Limit please go to www.ghp.georgia.gov, select Provider Information, click on "view full list" in the Medicaid Provider Manuals box then select Pharmacy Services from the list shown.